Skip to content

Asset turnover at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
0.5×+0.3×
LQD
Liquidia CorporationLQDA
0.9×+0.8×
Royalty Pharma logo
Royalty PharmaRPRX
0.1×0.0×
United Therapeutics logo
United TherapeuticsUTHR
0.4×0.0×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
0.5×0.0×
Precigen logo
PrecigenPGEN

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$890.32M+67.5%
Enterprise value$642.72M+37.0%
P/E7.8×
P/S8.1×0.0×

Profitability

See full
Gross margin60.8%
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Calculated from Theravance Biopharma’s reported figures.

Based on trailing twelve months.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Theravance Biopharma's asset turnover?
Theravance Biopharma (TBPH) reported asset turnover of 0.3× in Q1 2026.
How has Theravance Biopharma's asset turnover changed year-over-year?
Theravance Biopharma's asset turnover increased by 47.4% year-over-year, from 0.2× to 0.3×.
What is the long-term trend for Theravance Biopharma's asset turnover?
Over 5 years (2020 to 2025), Theravance Biopharma's asset turnover has grown at a 9.3% compound annual growth rate (CAGR), from 0.2× to 0.3×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.